A Randomised phase II study with the combination of Xeloda (Capecitabine) plus Navelbine Oral ( Vinorelbine) day 1 and day 8 every 3. week versus Xeloda plus Navelbine Oral given metronimic as 1. or 2. line chemotherapy to patients with HER2 negative local metastatic breastcancer.

Trial Profile

A Randomised phase II study with the combination of Xeloda (Capecitabine) plus Navelbine Oral ( Vinorelbine) day 1 and day 8 every 3. week versus Xeloda plus Navelbine Oral given metronimic as 1. or 2. line chemotherapy to patients with HER2 negative local metastatic breastcancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Capecitabine (Primary) ; Vinorelbine (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms XeNa
  • Most Recent Events

    • 27 Oct 2016 Status changed to completed.
    • 15 Sep 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01941771).
    • 22 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top